Bharat Biotech's partner seeks Covaxin approval in US for children below 18 years

By Rajan Nath -- November 06, 2021 11:11 am -- Updated:Feb 15, 2021

Bharat Biotech's US partner Ocugen has announced that it had asked the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18.

"We are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners- Ocugen," tweeted Dr Raches Ella, Bharat Biotech's clinical lead for Covid-19 vaccines.

Also Read | In resignation letter to Sonia Gandhi, Captain Amarinder calls Navjot Singh Sidhu ‘Pakistani acolyte’

Bharat Biotech's Covaxin gets shelf life extension up to 12 months from date of manufacture

The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) for Bharat Biotech's Covid-19 vaccine, Covaxin.

Also Read | Petrol, diesel prices in India reduced significantly after cut in excise duty

WHO approves Bharat Biotech's Covaxin for emergency use listing

The approval was done on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.

WHO panel to decide on Covaxin EUL tomorrow

Bharat Biotech's Covaxin and AstraZeneca and Serum Institute's Covishield are the two widely used vaccines in India.

-PTC News